Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV

Fig. 2

Comparison of Baseline Serum Levels of Chemokines/Cytokines of CHC, GT1 and IL28B-CC patients. (a) (f) (g) Pretreatment serum levels of CXCL9 (P = 0.916), IFN-γ (P = 0.525) and IL-10 (P = 0.662) showed no significant differences between NR and non-NR group of patients. (b) (c) (d) (e) NR group of patients showed higher baseline levels of CXCL10 (*P = 0.004), CXCL11 (*P < 0.001), CCL3 (*P = 0.005) and CCL4 (*P = 0.007) than non-NR group. Significance was assessed by means of the nonparametric Mann–Whitney test. Box plots represent medians and 25th–75th percentiles

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us